文献速递中毒与环境急症重症综合管理与镇静镇痛

局麻药全身毒性的临床特征、治疗与结局:一项10年回顾性研究

Clinical characteristics, treatment, and outcomes of local anesthetic systemic toxicity: a 10-year retrospective study.
PubMed 文献 · Clin Toxicol (Phila) · 2025-10-21
一句话结论局麻药全身毒性中,静脉给药、昏迷、低血压和心脏骤停是死亡的独立预测因素,脂肪乳剂治疗延迟是障碍。

该回顾性队列研究基于泰国拉玛提波迪中毒中心2013年1月至2022年12月数据,纳入143例局麻药全身毒性患者,中位年龄41.5岁,利多卡因最常见(89.5%),局部浸润(59.4%)和静脉给药(15.4%)为主要途径。神经症状为首发表现占78.3%,心血管症状占43.4%,心脏骤停占10.5%。多因素分析显示静脉给药(OR 5.59)、昏迷(OR 12.0)、低血压(OR 5.23)和心脏骤停(OR 210)为死亡的独立预测因素。12.6%患者接受静脉脂肪乳剂治疗,症状出现至给药中位时间63分钟,18例接受者中2例(11.1%)出现不良反应。

要点

  • 局麻药全身毒性患者中,心脏骤停者死亡风险极高(OR 210,95%CI 22-1919),需立即识别并处理。
  • 静脉给予局麻药是死亡的独立预测因素(OR 5.59,95%CI 1.53-20.33),应警惕该途径的毒性风险。
  • 初始昏迷(OR 12.0)和低血压(OR 5.23)与死亡率独立相关,床旁应重点评估意识与血压。
  • 静脉脂肪乳剂治疗在12.6%患者中使用,症状至给药中位延迟63分钟,资源有限环境下获取延迟是障碍。
  • 脂肪乳剂不良反应(ARDS和脂肪超载综合征)在接受者中占11.1%(2/18,95%CI 3.4-26%)。

适用人群与场景

  • 2013年1月至2022年12月期间在泰国拉玛提波迪中毒中心诊断为局麻药全身毒性的患者。

处置流程与药物剂量

  • 静脉脂肪乳剂治疗用于12.6%的患者,症状出现至给药中位时间63分钟(IQR 48-90分钟)。

红旗征与不能漏的情况

  • 初始昏迷(OR 12.0;95%CI 2.96-48.60)与死亡率独立相关。
  • 初始低血压(OR 5.23;95%CI 1.34-20.29)与死亡率独立相关。
  • 心脏骤停(OR 210;95%CI 22-1919)与死亡率独立相关。
  • 静脉给予局麻药(OR 5.59;95%CI 1.53-20.33)与死亡率独立相关。

研究设计与关键结果

  • 回顾性队列研究纳入143例患者,中位年龄41.5岁(IQR 27.0-56.0岁),利多卡因最常见(89.5%)。
  • 给药途径以局部浸润(59.4%)和静脉(15.4%)最常见。
  • 初始表现神经症状占78.3%(口周麻木、癫痫发作或昏迷),心血管症状占43.4%(胸痛、心悸、低血压和心脏骤停),心脏骤停占10.5%。
  • 多因素分析:静脉给药OR 5.59(95%CI 1.53-20.33)、昏迷OR 12.0(95%CI 2.96-48.60)、低血压OR 5.23(95%CI 1.34-20.29)、心脏骤停OR 210(95%CI 22-1919)为死亡的独立预测因素。
  • 静脉脂肪乳剂用于12.6%患者,症状至给药中位时间63分钟(IQR 48-90分钟);18例接受者中2例(11.1%[95%CI 3.4-26%])出现不良反应(急性呼吸窘迫综合征和脂肪超载综合征)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对局麻药全身毒性患者,初始出现低血压、昏迷或心脏骤停提示死亡风险显著升高,应积极复苏。
  • 静脉给予局麻药的患者发生毒性时死亡风险更高,需加强监测与处理。
  • 静脉脂肪乳剂治疗虽显示临床疗效,但症状至给药中位延迟63分钟,在 rural 或资源有限环境中获取延迟是障碍。
  • 接受静脉脂肪乳剂治疗者中11.1%出现ARDS或脂肪超载综合征等不良反应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Local anesthetic systemic toxicity is a rare but potentially life-threatening complication of local anesthetic use. This study aimed to describe the characteristics of patients with local anesthetic systemic toxicity and to identify initial clinical prognostic factors.

METHODS: A retrospective cohort study of patients diagnosed with local anesthetic systemic toxicity from January 2013 to December 2022 was conducted using data from the Ramathibodi Poison Center Toxic Exposure Surveillance System, Thailand.

RESULTS: One hundred and forty-three patients were included, with a median age of 41.5 years (IQR: 27.0-56.0 years). Lidocaine was the most commonly implicated local anesthetic (89.5%). The most frequent routes of administration were local infiltration (59.4%) and intravenous (15.4%). Neurological symptoms (perioral numbness, seizures, or coma) were the most common initial presentations (78.3%), followed by cardiovascular symptoms (43.4%), including chest pain, palpitations, hypotension, and cardiac arrest; cardiac arrest occurred in 10.5% of cases. Intravenous lipid emulsion therapy was administered in 12.6% of patients, and the median time from symptom onset to administration was 63 min (IQR: 48-90 min). Adverse effects of intravenous lipid emulsion (acute respiratory distress syndrome and fat overload syndrome) occurred in two of 18 (11.1% [95% CI:3.4-26%]) recipients. A multivariate analysis identified intravenous administration of local anesthetic (OR: 5.59; 95% CI: 1.53-20.33), the initial presence of coma (OR: 12.0; 95% CI: 2.96-48.60), hypotension (OR: 5.23; 95% CI: 1.34-20.29), and cardiac arrest (OR: 210; 95% CI: 22-1,919) as independent predictors of mortality.

DISCUSSION: Seizures were the most frequent initial neurological presentation in our study, followed by cardiovascular features, particularly hypotension and palpitations, which is consistent with previous reports of local anesthetic systemic toxicity.

CONCLUSIONS: In our study, the presence of hypotension, coma, and cardiac arrest at presentation and intravenous administration of local anesthetic was strongly associated with severe outcomes and increased mortality. Although intravenous lipid emulsion therapy has shown clinical efficacy, delayed access to this treatment remains a considerable barrier, particularly in rural or resource-limited settings.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Kaenphukhieo T, Trakulsrichai S, Tongpoo A, et al. Clinical characteristics, treatment, and outcomes of local anesthetic systemic toxicity: a 10-year retrospective study. Clin Toxicol (Phila). 2025. PMID: 41117381. doi:10.1080/15563650.2025.2563135

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。